Immunogenicity of Short-Course,High-Dose Hepatitis B Vaccination in Patients with Chronic Kidney Disease-Shanxi Province,China,2019-2020  

作　　者：Linying Gao Xufeng Cui Xinyuan Mo Zhaoyue Men Xiuyang Xu Tian Yao Jianmin Wang Hongting Liu Hongping Guo Guowei Chai Liming Liu Fuzhen Wang Xiaofeng Liang Suping Wang Yongliang Feng 

机构地区：[1]School of Public Health,Shanxi Medical University,Taiyuan City,Shanxi Province,China [2]Key Laboratory of Coal Environmental Pathogenicity and Prevention(Shanxi Medical University),Ministry of Education,Taiyuan City,Shanxi Province,China [3]Center of Clinical Epidemiology and Evidence Based Medicine,Shanxi Medical University,Taiyuan City,Shanxi Province,China [4]First Hospital/First Clinical Medical College of Shanxi Medical University,Taiyuan City,Shanxi Province,China [5]Department of Nephrology,Linfen Central Hospital,Linfen City,Shanxi Province,China [6]Department of Nephrology,Yuncheng Central Hospital,Yuncheng City,Shanxi Province,China [7]Department of Nephrology,Linfen People’s Hospital,Linfen City,Shanxi Province,China [8]Department of Nephrology,Houma People’s Hospital,Houma City,Shanxi Province,China [9]National Immunization Program,Chinese Center for Disease Control and Prevention,Beijing,China [10]Institute of Vaccine Industry,Jinan University,Guangzhou City,Guangdong Province,China [11]Institute of Disease Control and Prevention,Jinan University,Guangzhou City,Guangdong Province,China [12]Chinese Preventive Medicine Association,Beijing,China

出　　处：《China CDC weekly》2024年第50期1331-1336,I0002-I0005,共10页中国疾病预防控制中心周报（英文）

基　　金：Supported by the National Science and Technology Major Project of the Ministry of Science and Technology of the People’s Republic of China under Grant[2018ZX10721202];the Key Research and Development Program of Lvliang under Grant[2020SHFZ52];the Key Research and Development Program of Science and Technology of Linfen under Grant[2136].

摘　　要：What is already known about this topic?As one of the populations at high risk of hepatitis B virus(HBV)infection,patients with chronic kidney disease(CKD)require rapid and effective development of hepatitis B surface antibodies(anti-HBs).What is added by this report?The short-course,high-dose regimen of hepatitis B vaccination rapidly induced comparable immunological responses to the routine regimen,achieving a seroconversion rate of 88.5%,a high-response rate of 64.1%,and anti-HBs geometric mean concentrations of 824.1 mIU/mL.What are the implications for public health practice?The short-course,high-dose regimen represents an effective rapid immunization strategy for CKD patients,particularly when administered prior to immunosuppressive therapy.This study provides compelling evidence for optimizing immunization protocols in the CKD population.

关 键 词：ROUTINE KIDNEY SHANXI 

分 类 号：R512.62[医药卫生—内科学] R186[医药卫生—临床医学]